people sustain a traumatic brain injury globally each year1
Developing therapies
for recovery after
brain injury
Summation Therapeutics is developing novel treatments for the neuropsychiatric and functional consequences of traumatic brain injury.
The unmet need
A significant burden.
Limited options.
Many people continue to experience symptoms after traumatic brain injury. Current care is often fragmented and symptom-specific, leaving a critical need for therapies designed around recovery and function.
may develop persistent symptoms after mild TBI2
estimated annual U.S. economic burden of TBI3
1. Feigin et al., Lancet Neurol. 20212. Silverberg et al., JAMA Neurol. 20213. Florence et al., JAMA Surg. 2018
Our approach
Science-driven.
Patient-focused.
Purpose-built.
We are advancing a focused development strategy designed to restore neuropsychiatric balance and improve functional recovery after brain injury.
Focused pipeline
Prioritizing high-need indications with biological rationale and meaningful clinical potential.
Biology guided
Connecting neuroscience, patient symptoms, and functional outcomes to inform development.
Designed for patients
Focusing on the symptoms and functional consequences that matter to patients and caregivers.
Our lead program
Opipramol for mTBI
A repurposed, multimodal therapy with decades of clinical experience. Summation is studying opipramol as an early intervention for neuropsychiatric symptoms and functional impairment after mild traumatic brain injury.
A Disciplined Framework for TBI Development
Define the recovery problem
Focus on a specific consequence of brain injury, a defined patient population, and a clinically meaningful treatment window.
Connect biology to the patient
Use modern TBI neuroscience and patient presentation to identify where a therapy has the strongest rationale to work.
Test one decisive clinical question
Design rigorous studies around a clear proof-of-concept question and outcomes that matter to patients and clinicians.
Let the evidence guide development
Define success and failure in advance, then use the result to advance, refine, or stop the program.
News
Company updates.
Scientific, intellectual-property, and development updates from Summation Therapeutics.
Summation Therapeutics Announces Notice of Allowance for U.S. Patent Application Relating to Opipramol After Concussion
The United States Patent and Trademark Office has issued a Notice of Allowance for claims in a Summation Therapeutics patent application relating to the use of opipramol following concussion.
Read the releaseOur mission is to develop therapies that meaningfully improve recovery and quality of life after brain injury.
info@summationtx.com